[Post-menopausal endometriosis developed during tamoxifen treatment].

Le Bouëdec G, G. Le Bouëdec, P. Kauffmann, Kauffmann P, Pingeon JM, J. M. Pingeon, de Latour M, M de Latour, P. Lemesle, Lemesle P, J Dauplat, Dauplat J
Revue francaise de gynecologie et d'obstetrique · 1991 · vol. 86(5) , pp. 407–10 · PMID:1871504 · W2236644252
article OA: closed CC0 ⤵ 6 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

A 69-year-old post-menopausal woman developed endometriosis and endometrioma during seven years of tamoxifen treatment for breast cancer.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The authors report a case of endometriosis (adenomyosis + endometrioma) which occurred in a female patient aged 69 years, who had undergone the menopause 15 years previously and who had been taking Tamoxifen for 7 years as an adjuvant treatment for cancer of the breast. Tamoxifen, a non-steroidal anti-estrogen derived from diethylstilbestrol, has a variable antagonist/agonist so that estrogenic stimulation of the female genital tract may occur, particularly of the endometrial mucosa. The reactivation of the endometriosic foci which had become quiescent under the impact of the natural menopause, which, by iatrogenic analogy is included in the series of paradoxical uterine effects of tamoxifen.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosisendometrioma

MeSH descriptors

Endometriosis Ovarian Neoplasms Tamoxifen Aged Endometriosis Female Humans Menopause Ovarian Neoplasms Tamoxifen

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (6)

Source provenance

europepmc
last seen: 2026-09-09T06:15:24.302764+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:12:00.397535+00:00
License: CC0 · commercial use OK